Vascular endothelial growth factor A (VEGFA) is a specific mitogen for vascular endothelial cells that plays a critical role in cancer neoangiogenesis. Here, we report that the nucleolar tumor suppressor p19 ARF suppresses VEGFA expression, acting at the level of mRNA translation without affecting the transcription of the VEGFA gene. 
Introduction
The INK4a/ARF locus encodes two tumor suppressor proteins, p16
INK4a and p19 ARF (p14 ARF in humans; refs. 1, 2), that indirectly activate retinoblastoma protein and p53 (3) . These proteins comprise a complex signaling network that regulates checkpoint responses to oncogenic stresses by halting the cell cycle and/or eliminating cells that have sustained irreparable damage (4) (5) (6) . As the inactivation of these genes allows cells that sustain oncogenic insults to survive and proliferate, their loss of function through deletion, mutation, or epigenetic silencing is detected in most cancers (3, 7) . p19 ARF physically associates with mdm2, a negative regulator of p53; relocalizes it to the nucleolus (8) ; and inhibits its E3 activity toward p53 protein, which results in the stabilization of p53 (9) . Stabilized p53 protein activates the transcription of genes including p21
Cip1 and Bax, thereby inducing cell cycle arrest or apoptosis (10) . In addition to its p53-dependent activity, p19 ARF also induces cell growth inhibition independently of the p53 pathway. ARF/p53 double knockout (DKO) mice have a greater risk of developing malignant tumors than ARF or p53 single knockout mice (11, 12) . This suggests that p19 ARF inhibits tumor development both through p53-dependent and p53-independent pathways. Although the molecular mechanism involved in its p53-independent function remains unknown, we and other groups have shown that ARF protein inhibits the processing of rRNA through interactions with a nucleolar protein, nucleophosmin (NPM)/B23 (13) (14) (15) .
Besides its cell autonomous effects on tumor development, ARF also regulates angiogenic signaling. p14 ARF inhibits the activity of hypoxia-inducible factor 1α (HIF1α), which is a critical transcription factor for vascular endothelial growth factor A (VEGFA) expression (16) (17) (18) . Additionally, INK4a/ ARF-null colon tumors developed in Min mice, which harbor a mutation in the adenomatous polyosis coli gene, have increased VEGF content and more vascular structures than those carrying the wild-type INK4a/ARF alleles (19) . VEGFA is a key mediator of angiogenesis (20) and also acts as a potent tumor angiogenic factor (21) . Solid tumors can only grow to a limited size without an adequate vascular supply due to a lack of oxygen and nutrients. VEGFA stimulates the growth of new blood vessels from adjacent microvessels, thereby allowing tumors to obtain oxygen and nutrients (21, 22) . In addition to the transcriptional control mechanisms exerted on it, the expression of VEGFA is also regulated at the translational level through its internal ribosome entry sequence (IRES; refs. 23, 24) . The IRES of VEGFA is located in the 5′ untranslated region (UTR) from the transcription initiation site, and the IRES sequence is highly conserved among humans, mice, bovines, and rats (25) .
Here, we show that p19 ARF inhibits the translation of VEGFA mRNA. The translational regulation of VEGFA mRNA by p19
ARF involves the regulation of VEGFA IRES activity. Although p53 is dispensable for the repression of VEGFA translation, NPM/B23 seems to be involved in VEGFA regulation. Tumor angiogenesis is inhibited by p19 ARF in vivo in the absence of p53, with a concomitant reduction in the VEGFA protein level, and the expression of p14 ARF inversely correlates with tumor vascularity in human colon carcinoma. Taken together, these findings reveal a novel function of the ARF tumor suppressor-its engagement in the translational regulation of specific oncogenes.
Materials and Methods

Plasmids
pcDNA3 Flag-NPM/B23, MSCV-GFP Flag-NPM/B23 (14) , and MSCV-GFP p19 ARF (26) were provided by Dr. Charles J. Sherr (Howard Hughes Medical Institute/St. Jude Children's Research Hospital, Memphis, TN). pcDNA3 Flag-p21 was provided by Dr. Eiji Hara (Cancer Institute, Tokyo, Japan). pBabeRas (V12) was provided by Dr. Manuel Serrano (Spanish National Cancer Research Center, Madrid, Spain). To construct MSCV VEGFA 165 , murine VEGFA cDNA was obtained by PCR using the following primers: sense 5′-AAGGATC-CACCGCCATGAACTTTCTGC-3′, antisense: 5′-AACTCGAG-TCACCGCCTTGGCTTGTCAC-3′. The PCR product digested with BamHI and XhoI was cloned into the MSCV-GFP vector. To construct MSCV p19 ARF A4-6, mutant cDNA was obtained from pSRα HA-p19 ARF A4-6 (provided by Dr. Charles J. Sherr; ref. 27 ) by PCR using the following primers: sense 5′-AAAGG-ATCCACCGCCATGGGTCGCAGGGTCGCAGGTTCTTGGT-3′, antisense 5′-AAACTCGAGCTATGCCCGTCGGTCTGGGC-3′. The PCR product was cloned into the MSCV vector as described above. For the luciferase reporter assay, we used IRES reporter plasmids containing Renilla luciferase (RL) and cistronic Firefly luciferase (FF) or pCMV RL-FF (pLL) containing mouse or human VEGFA IRES between RL and FF (ref. 28 ; gifts from Dr. Orna Elroy-Stein, Tel Aviv University, Tel Aviv, Israel).
Cell culture and virus production
NIH-3T3 cells were maintained in Dulbecco's modified Eagle's medium containing 10% FCS, 2 mmol/L glutamine, and 100 U/mL each of penicillin and streptomycin. Mouse embryonic fibroblasts (MEF) were cultured in medium supplemented with 0.1 mmol/L MEM nonessential amino acids (Invitrogen). For retrovirus production, 293T cells were transfected with helper plasmids together with MSCV vectors containing cDNA as described elsewhere (5) . The viruses were harvested 24 to 60 hours posttransfection. Exponentially growing cells were infected with fresh virus-containing supernatant containing 8 μg/mL polybrene (Sigma Chemicals). Ras or sh-NPM-infected cells were selected with puromycin (5 μg/mL). Retroviral transduction of the p19 ARF , VEGFA, and Flag-NPM/B23 genes was confirmed by immunofluorescence or green fluorescent protein.
Luciferase reporter assay
Cells (5 × 10 4 /35 mm culture dish) were transfected with 100 ng of the IRES reporter plasmid and 500 ng of the control or p19 ARF plasmid using FuGENE6 (Roche Diagnostics). Three days later, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega).
Immunoblotting and ELISA
Lysates were prepared using Tween 20 lysis buffer [50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 2.5 mmol/L EGTA, 10% glycerol, 1 mmol/L DTT, and 0.1% Tween 20] containing protease inhibitors. For the preparation of conditioned medium, cells were cultured in 0.5 mL of medium containing 5% FCS in 35-mm culture dish. Four days later, the medium was collected and the protein concentration of each sample was equalized. Samples were boiled in a reducing sample buffer containing 5% β-mercaptoethanol, 10% glycerol, 1% SDS, 50 mmol/L Tris (pH 6.8), and 0.025% bromophenol blue, separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore). Proteins were detected using antibodies to VEGFA (C-1, Santa Cruz Biotechnology), NPM (FC-61991, Zymed Laboratories), p19 ARF (5-C3-1, Santa Cruz Biotechnology), CDK4 (C-22, Santa Cruz Biotechnology), Ras (BD Biosciences), and α-tubulin (B-5-1-2, Sigma Chemicals).
VEGFA concentration was measured using Mouse VEGFA Quantikine ELISA Kit (R&D Systems).
RNA analyses
RNA was extracted using TRI Reagent (Sigma Chemicals). Polysomal RNA was prepared as described previously (29) . For Northern blotting, RNA separated on a 1% formaldehydeagarose gel was transferred to Hybond N + membranes (Amersham Bioscience) and radiolabeled probes were hybridized.
For real-time PCR analysis, RNA was treated with DNase I (Invitrogen) and cDNA was generated using the PrimeScript RT kit (TAKARA BIO). Real-time PCR analysis was carried out on Chrormo4 (Bio-Rad) using the following primers: VEGFA (sense 5′-GCACATAGGAGAGATGAGCTTCC-3′, antisense 5′-CTCCGCTCTGAACAAGGCT-3′) and 18S rRNA (sense 5′-AGTCCCTGCCCTTTGTACACA-3′, antisense 5′-GATCCGAGGGCCTCACTAAAC-3′).
Tumorigenesis assay
ARF/p53 DKO MEF infected with the Ras retrovirus together with control or p19 ARF retroviruses were s.c. injected (2 × 10 6 per mouse) into the right flanks of 6-week-old nu/nu mice. Fourteen days later, mice were sacrificed and tumors were analyzed.
Immunofluorescence and immunohistochemistry
Cells on coverslips were washed thrice in PBS and fixed for 15 minutes in 1:1 methanol/acetone at −20°C. The dried coverslips were rehydrated in PBS, blocked for 30 minutes with 5% FCS in PBS, and incubated with VEGFA antibody (2 μg/mL) for 60 minutes. Following three rinses in PBS, the coverslips were incubated for 30 minutes with FITC-conjugated anti-mouse IgG (Amersham Bioscience) and counterstained with 4′,6-diamidino-2-phenylindole (DAPI).
Indirect immunohistochemical staining of formaldehydefixed, deparaffinized tissue sections was carried out after antigen retrieval by boiling the sections in a microwave oven for 10 minutes in 10 mmol/L citric acid (pH 6.0). Mouse tumor sections were stained using anti-CD31 (M20, Santa Cruz Biotechnology) and visualized using the Vectastain Elite kit (Vector) with 3,3′-diaminobenzidine substrate. Human colon carcinoma sections (Shanghai Outdo Biotech) were stained with CD31 and p14 ARF antibodies (4C6/4, Cell Signaling Technology), and p14 ARF was visualized using Alexa488-conjugated secondary antibody (Invitrogen) before DAPI staining.
Results
p19
ARF represses VEGFA expression To test whether p19 ARF affects VEGFA expression, NIH-3T3 cells were infected with control or p19 ARF expression retroviruses, and VEGFA protein levels were analyzed. As shown, the expression of p19 ARF resulted in a significant decrease in the VEGFA protein level ( Fig. 1A and B). As NIH-3T3 cells retain wild-type p53 alleles and p19
ARF exerts both p53-dependent and p53-independent functions in these cells, we examined whether p53 is required for VEGFA repression by p19 ARF . For this purpose, p19 ARF was retrovirally expressed in ARF/p53 DKO MEF, and VEGFA proteins in cell lysates and conditioned media were analyzed. Similar to the case in NIH-3T3 cells, the concentration of VEGFA protein in both the cell lysates and conditioned medium was diminished by p19 ARF in the ARF/p53 DKO MEF ( Fig. 1C and D) . The effect of p19 ARF was slightly less pronounced in these cells; therefore, the p53 pathway may also contribute to p19 ARF -induced VEGFA repression. We next tested whether endogenous p19 ARF suppresses VEGFA expression by comparing VEGFA levels between ARF/p53 DKO and p53 KO MEF. VEGFA expression was lower in the p53 KO MEF than in the ARF/p53 DKO MEF ( Supplementary Fig. S1A and B). These results suggest that p19
ARF suppresses VEGFA expression and that p53 is not a prerequisite for VEGFA suppression.
ARF suppresses the translation of VEGFA mRNA It has been reported that p53 suppresses the transcription of VEGF in human sarcoma cells (30) . However, our above results indicate that p19 ARF represses VEGFA expression in the absence of p53. Hence, we next examined how p19 ARF affects VEGFA expression. We first checked whether the transcription of the VEGFA gene is suppressed by p19 ARF in NIH-3T3 cells and ARF/p53 DKO MEF. Despite the reduction of the VEGFA protein ( Fig. 1), p19 ARF had no influence on the transcription of the VEGFA gene in these cells ( Fig. 2A) , ARF -expressing retroviruses were immunostained using VEGFA antibody. C, extracts or conditioned medium of ARF/p53 DKO MEF infected with control or p19 ARF retroviruses were analyzed. D, VEGFA in cell lysate (left) and conditioned medium (right) from ARF/p53 DKO MEF were measured by ELISA.
suggesting that it posttranscriptionally affects VEGFA expression. We next checked whether p19 ARF regulates the translation of VEGFA mRNA. Cytoplasmic lysates prepared from NIH-3T3 cells or ARF/p53 DKO MEF infected with control or p19 ARF expression retroviruses were fractionated into polysome/nonpolysome fractions by sucrose gradient sedimentation. RNAs recovered from polysome fractions were analyzed to assess their VEGFA mRNA levels. In both NIH-3T3 cells and ARF/p53 DKO MEF, the VEGFA mRNA levels were decreased in the polysome fractions in the presence of p19 ARF (Fig. 2B) . Similar results were obtained by Northern blotting (Fig. 2C and D) : VEGFA mRNA was mainly observed in the polysome fractions in the absence of p19 ARF but was redistributed to the nonpolysome fractions after p19 ARF expression, whereas β-actin mRNA was unaffected. These results indicate that p19 ARF suppresses VEGFA expression mainly through translational control.
ARF inhibits the IRES activity of VEGFA mRNA The translation of VEGFA mRNA is regulated through IRES in its 5′UTR (23, 24) . As p19 ARF was found to suppress the translation of VEGFA mRNA, we next tested whether p19
ARF affects VEGFA-IRES activity. To this end, IRES reporter plasmids, which expressed a bicistronic mRNA (Renilla luciferase-VEGFA IRES-Firefly luciferase) under the regulation of the CMV promoter, were transfected into NIH-3T3 cells together with the p19 ARF expression plasmid. As shown in Fig. 3A , the IRES activity of both mouse and human VEGFA mRNA (mVEGFA and hVEGFA 5′UTR, respectively) was suppressed by p19 ARF . Northern blot analyses using a Renilla or Firefly luciferase probe indicated that the cells expressed single mRNA species in the presence or absence of p19 ARF , demonstrating that there was little, if any, cryptic promoter activity in these plasmids (Fig. 3A, right) . The expression of p19 ARF leads to cell cycle arrest through p53-mediated p21
Cip1 induction in NIH-3T3 cells. To assess whether the inhibition of VEGFA IRES activity is attributed to p21
Cip1 -dependent cell cycle arrest, an IRES reporter assay was performed in the presence of the p21
Cip1 expression plasmid. The expression of p21
Cip1 did not inhibit VEGFA IRES, therefore suggesting that IRES repression by p19 ARF is not caused by p21
Cip1 -mediated cell cycle arrest (Fig. 3B) . Moreover, p19 ARF suppressed both mouse and human VEGFA IRES activity in ARF/p53 DKO MEF, in which p21
Cip1 is not induced Figure 2 . VEGFA is translationally suppressed by p19 ARF . A, VEGFA mRNA levels in NIH-3T3 cells and ARF/p53 DKO MEF infected with control or p19 ARF -expressing retroviruses were analyzed by real-time PCR. Values were normalized to GAPDH mRNA levels. B, VEGFA mRNA levels in polysomal fractions in NIH-3T3 cells and ARF/p53 DKO MEF infected with the indicated retroviruses were analyzed by real-time PCR. Values were normalized to the levels of 18S rRNA. C, the cytoplasmic fraction prepared from NIH-3T3 cells infected with the indicated retroviruses was fractionated into polysomal and nonpolysomal fractions. The distribution of VEGFA and β-actin mRNA in these fractions was analyzed by Northern blotting. 28S and 18S rRNAs were visualized using ethidium bromide. D, the intensity of VEGFA and β-actin mRNA signals in C was quantified using ImageJ.
by p19 ARF (Fig. 3C) , further supporting the notion that translational repression of VEGFA by p19 ARF does not require the p53 pathway. Likewise, the VEGFA IRES activity in the p53 KO MEF was lower than that in the ARF/p53 DKO MEF, suggesting that endogenous p19 ARF suppresses VEGFA IRES activity (Supplementary Fig. S1C ).
ARF suppresses VEGFA expression through NPM/B23 Because p19 ARF does not require the p53 pathway to suppress VEGFA, we next sought a mediator for the VEGFA regulation. We and others have reported that p19 ARF associates with NPM/B23 independently of mdm2 (14, 15, 31) . To clarify whether mdm2 interaction is required for the regulation of VEGFA by p19 ARF , we used a mutant form of p19 ARF , which contains Ala substitutions for Phe23, Leu47, and Arg54 (p19 ARF A4-6). This p19 ARF mutant retains the ability to induce p53-dependent cell cycle arrest through its interaction with mdm2 but is incapable of binding to NPM/B23 (27) . NIH-3T3 cells were transfected with the VEGFA IRES reporter plasmid together with a wild-type or mutant p19 ARF plasmid. Under these conditions, wild-type p19 ARF suppressed VEGFA IRES activity; however, p19 ARF A4-6 failed to do so (Supplementary Fig. S2A ). These results indicate that p19 ARF -mdm2 interaction is not responsible for VEGFA IRES repression.
The p19 ARF -NPM/B23 association leads to the downregulation of NPM/B23 through ubiquitylation (15, 32) . We therefore tested whether the downregulation of NPM/B23 is sufficient to induce VEGFA repression. To this end, we knocked down endogenous NPM/B23 using short hairpin (sh) RNA. sh-NPM/B23 sufficiently decreased the NPM/B23 level (ref. 27 ; Fig. 4A ). Under these conditions, both the VEGFA protein level and IRES activity were diminished ( Fig. 4A and B) .
Next, we investigated the effect of NPM/B23 on p19 ARFmediated VEGFA repression. NIH-3T3 cells and ARF/p53 DKO MEF were infected with NPM/B23 retroviruses together with control or p19 ARF retroviruses. The expression of p19 ARF led to the reduction of the levels of VEGFA as well as NPM/ B23, and overexpression of Flag-NPM/B23 restored the VEG-FA level in the presence of p19 ARF in both types of cells ( Fig. 4C; Supplementary Fig. S2B ). Similarly, p19
ARF was not able to inhibit VEGFA IRES activity in the presence of exogenous NPM/B23 (Fig. 4D) . On the other hand, overexpression of NPM/B23 did not further increase the VEGFA level (Fig. 4C) , suggesting that the endogenous NPM/B23 level is sufficient to maintain VEGFA expression.
ARF inhibits VEGFA-dependent tumor angiogenesis in vivo VEGFA is a key regulator of blood vessel formation and plays an essential role in angiogenesis, which contributes to the development of tumors, and its expression correlates well with tumor malignancy. As our above results suggest that p19
ARF suppresses VEGFA expression, we next examined whether VEGFA suppression contributes to the tumor suppressor activity of p19 ARF . ARF/p53 DKO MEF were infected with retroviruses encoding oncogenic Ras (V12) together with control or p19 ARF expression retroviruses. p19 ARF was able to downregulate VEGFA protein levels in Ras-transformed ARF/ p53 DKO MEF (Fig. 5A ). Under these culture conditions, p19 ARF had little impact on the proliferation of Rastransformed ARF/p53 DKO MEF (Supplementary Fig. S3A) . These cells were then s.c. transplanted into the athymic mice. Following transplantation, the sizes of tumors arising in each mouse were measured up to 14 days. There was no obvious difference in tumor size among these mice within the first week after transplantation. However, tumors from the control virus-infected cells began to grow faster than those from the p19 ARF -expressing cells, suggesting that p19 ARF retards tumor progression in the absence of p53 (Supplementary Fig. S3B ). We then analyzed microvessel formation within these tumors. Tumor sections prepared from each mouse were immunostained using anti-CD31, a marker of blood vessel endothelial cells. In tumors that showed p19 ARF expression, microvessel density was significantly lower than that observed in control samples (Fig. 5B) .
Next, we examined whether the reduced microvessel formation observed within tumors expressing p19 ARF was attributable to the decreased production of VEGFA protein.
To this end, Ras-transformed ARF/p53 DKO MEF were infected with retroviruses encoding VEGFA in the absence or presence of p19 ARF retroviruses. The exogenous VEGFA protein levels were not affected by p19 ARF because of the lack the IRES sequence required for its expression (Fig. 5C ). As in the experiments above, p19 ARF did not affect the proliferation rate of the cells expressing exogenous VEGFA under the culture conditions (Supplementary Fig. S3C ). These cells were s.c. injected into athymic mice, and tumor size was monitored. The expression of exogenous VEGFA was sufficient to overcome the effect of p19 ARF on tumor development ( Supplementary Fig. S3D ). Microvessel density within the tumors increased in the presence of exogenous VEGFA as expected, and p19 ARF had no influence on exogenous VEGFAdriven angiogenesis (Fig. 5D ). Taken together, these results suggest that p19 ARF suppresses VEGFA-dependent tumor development and angiogenesis in the absence of p53.
Our results suggest that overexpression of NPM/B23 overcomes the effect of p19 ARF on VEGFA in vitro (Fig. 4) . Consistently, ectopically expressed NPM/B23 also restored tumor angiogenesis and development in the presence of p19 ARF ( Supplementary Fig. S4 ).
Expression of p14 ARF inversely correlates with microvessel density in human colon carcinoma
Because the above results suggest that ARF negatively regulates tumor angiogenesis, we next examined whether there was any correlation between ARF expression and microvessel formation in human cancer specimens. Sections prepared from 61 individual colon carcinoma patients were subjected to immunohistochemical analysis of ARF expression and microvessel density. Of these, 15 samples showed distinct nucleolar signals for p14 ARF antibody within the tumor cells, whereas 46 other samples had no specific staining patterns ( Fig. 6A and B) . These sections were stained with CD31 antibody, and the number of CD31-positive spots per area in each section was counted. As shown, the p14 ARF -positive samples contained fewer microvessels than the p14 ARF -negative samples (Fig. 6C) , supporting the view that ARF protein restricts vascularization in human cancers.
Discussion
VEGFA is a potent angiogenic factor that plays essential roles in the pathogenesis of diseases characterized by neoangiogenesis including cancers. Tumor cells trigger angiogenic switches to grow, and vasculature thereby develops to allow effective supply of oxygen and nutrients (21) . Hence, VEGFA is expected to be a potent target for cancer therapy, and certain anticancer drugs are known to counteract VEGFA activity (33, 34) . It has been reported that p53 negatively regulates the transcription of the VEGFA gene through the inhibition of HIF1α (30) . p14
ARF also impedes HIF1α-mediated transcription by sequestering it in the nucleoli (18). Our results, however, indicate that in mouse fibroblasts, p19 ARF predominantly affects the translation of VEGFA mRNA both in the presence and absence of p53. p19 ARF probably inhibits IRES-dependent VEGFA mRNA translation as our luciferase reporter analyses showed that p19 ARF had a suppressive effect on VEGFA IRES activity. The molecular mechanism underlying VEGFA IRES control remains obscure, and recent reports have suggested that factors that associate with VEGFA mRNA 3′UTR, such as miR-16 and IFN-γ-activated inhibitor of translation complex, also participate in the translational regulation of VEGFA (35) (36) (37) . The IRES reporter vectors used in this study did not contain the 3′UTR of VEGFA mRNA and therefore underestimated the effects of 3′UTR-mediated translational regulation. Thus, it is of interest to evaluate the contribution of 3′UTR to the translational control of VEGFA mRNA by p19 ARF . p19
ARF exclusively localizes to the nucleoli (1), where it associates independently with mdm2 and NPM/B23. p19
ARF -NPM/B23 interaction is required for the inhibition of large subunit rRNA (28S and 5.8S) maturation (14, 15) . It has been reported that cells carrying a hypomorphic mutation in the DKC1 gene (DKC1 m cells) also show defective large subunit rRNA maturation due to reduced pseudouridine synthesis (38) . Interestingly, DKC1 m cells are unable to direct the IRES-mediated translation of mRNA, including that of p27
Kip1 and Bcl-xl (39). However, p19 ARF failed to repress the activity of p27
Kip1 IRES ( Supplementary Fig. S5 ), suggesting that the inhibition of VEGFA IRES activity may not be attributed to the defective rRNA maturation commonly observed in ARF-expressing and DKC1 m cells. p14 ARF was shown to inhibit global protein synthesis by interfering with polysome formation (40) . Therefore, translational repression of VEGFA may merely reflect such global effects of ARF protein. However, this is unlikely because the effect of p19 ARF was restricted to VEGFA and PDGFB IRESes among the targets that we tested, and p27
Kip1 , p53, c-myc, and EMCV IRESes were not affected ( Supplementary Fig. S5 ). Furthermore, real-time PCR-based array analysis of polysomal mRNA suggests that only some genes are translationally regulated by p19 ARF . 4 Questions still remain as to how such translational regulation specificity is conferred and also how the nucleolar ARF protein affects cytoplasmic events. Our results at least suggest that NPM/B23 mediates the effect of p19 ARF on VEGFA expression due to the following reasons: (a) p19 ARF A4-6, which interacts with mdm2, but not with NPM/B23, was unable to suppress VEGFA IRES activity; (b) both human and mouse ARF protein have been shown to downregulate NPM/B23 (15, 32) ; and (c) the reduction of the NPM/B23 level by sh-NPM/B23 mimicked the effects of p19 ARF on VEGFA expression and VEGFA IRES activity. Ectopic expression of NPM/B23 fully abrogated the effects of p19 ARF on VEGFA expression, VEGFA IRES activity, and tumor angiogenesis. Thus, p19
ARF probably regulates VEGFA translation through NPM/B23 downregulation. However, given that ARF interacts 4 Our unpublished results. ARF expression inversely correlates with microvessel density in human cancers. A and B, human colon carcinoma sections (61 samples in total) were stained using p14 ARF and CD31 antibodies. p14 ARF was visualized using an FITC-conjugated secondary antibody, whereas CD31 was visualized using peroxidase. Fifteen out of a total of 61 samples showed distinctive nucleolar staining with p14 ARF antibody (A), whereas no specific signal was observed in the other 46 samples (B). C, the number of CD31-positive microvessels per area was counted in each tumor section. Bars represent mean values (full-length blots are presented in Supplementary Fig. S6 ).
with a large number of proteins (41) and that NPM/B23 may simply sequester p19
ARF from other ARF-interacting molecules (32) , it is difficult to exclude the possibility that an ARF-interacting protein other than NPM/B23 and mdm2 is responsible for VEGFA regulation.
Consistent with reduced VEGFA levels, tumors arising from ARF-expressing cells contain significantly fewer blood vessels. In addition, ARF/Ink4a-null colon tumors developed in Min mice were found to contain more VEGF and blood vessels than those grown in a wild-type ARF/Ink4a background (19) . Such a non-cell autonomous antitumor effect of ARF is probably conserved between humans and mice, as our study revealed that ARF expression inversely correlates with blood vessel density in human colon carcinomas. Tumor angiogenesis also plays an essential role in tumor metastasis. We did not detect any metastatic tumors in nude mice, and we were unable to assess the effect of ARF on metastasis. Nevertheless, others have reported that p19 ARF suppressed the growth and metastasis of tumors (42, 43) . Furthermore, the first exon (exon 1β) of the ARF gene is selectively deleted in metastatic melanoma cells (44) . Thus, together with our findings, p19 ARF may suppress tumor metastasis through the translational repression of VEGFA, which further supports the notion that vascular generation and tumor progression are accelerated as a consequence of inactivation of the ARF/Ink4a locus in human cancer.
In addition to its role in tumor angiogenesis, p19 ARF may also regulate eye development through translational regulation. ARF-null mice are blind and contain a dense fibrovascular tissue in the vitreous layer behind their eye lens (45) , which represents the accumulation of perivascular cells enveloping the vitreous component of hyaloid cells. Although the hyaloid vascular system normally regresses in the postnatal period in mice, no such regression is observed in ARF knockout animals. This p19 ARF function in eye development does not require p53 but is mediated through the downregulation of PDGF receptor β (Pdgfrb) mRNA (46) . Although the level of VEGFA may remain unchanged in the eyes of ARFnull animals, it is still possible that the expression of VEGFA is enhanced due to a lack of translational repression, which may contribute to the inhibition of hyaloid vascular regression. Additionally, p19
ARF may also suppress IRES-mediated PDGFB translation (Supplementary Fig. S5 ), which might cause impaired hyaloid vascular regression, although we were unable to evaluate the effect of ARF on PDGFB expression because the cells we used in this study did not express sufficient amounts of PDGFB mRNA for analysis.
We show a novel p53-independent function of the ARF tumor suppressor; that is, the inhibition of IRES-dependent translation of VEGFA. It has been reported that polymyelocytic leukemia protein inhibits the translation of HIF1α mRNA through the nuclear accumulation of mammalian target of rapamycin, which leads to the transcriptional repression of VEGF genes (47) . Although the detailed roles and molecular mechanisms of translational regulation in tumorigenesis remain to be clarified, it would be useful to target the translational machinery as a way of enhancing antiangiogenic and anticancer therapies.
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